Drug intelligence / Profile preview

erythropoietin + umbilical cord blood

Development stage: Unknown
Lead developer: CHA University
Modality: Cell Therapies, Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

A combination therapy that utilizes human umbilical cord blood cells (hUCBC) and recombinant human erythropoietin (rhEPO) to treat neurological conditions, particularly cerebral palsy and stroke. The therapy works through synergistic effects that enhance neurogenesis, angiogenesis, neuroprotection in the injured brain. EPO is typically administered before UCB infusion, with follow-up EPO injections at regular intervals afterward. This combination has shown superior efficacy compared to either component alone in clinical trials.

Other names: umbilical cord blood and erythropoietin combination therapyUCB + rhEPO

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on erythropoietin + umbilical cord blood.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on erythropoietin + umbilical cord blood.

Explore the full profile